透析前使用达依泊汀治疗贫血与临床结局:TREAT 试验分析
TREAT 试验事后分析纳入 590 例进展至透析的 2 型糖尿病合并慢性肾脏病患者,比较达依泊汀与安慰剂对透析起始后 180 天内结局的影响。达依泊汀组透析时血红蛋白更高(11.3±1.6 vs 9.5±1.5 g/dL,P<0.001),但全因死亡、心血管死亡、非致死性心肌梗死或心力衰竭风险无差异,卒中发生更高。
要点
- 透析前达依泊汀治疗未降低透析起始后 180 天内死亡、心梗或心衰风险。
- 达依泊汀组卒中发生 8 例(2.8%),安慰剂组 1 例(0.3%),HR 8.6(95% CI 1.1-68.7)。
- 该事后分析提示对接近透析的 2 型糖尿病合并 CKD 患者使用 ESA 需权衡卒中风险。
核心结论
- 透析前使用达依泊汀虽使透析起始时血红蛋白更高,但未降低透析后 180 天内全因死亡、心肌梗死或心力衰竭风险,且卒中发生频率更高。
研究设计与样本
- TREAT 随机对照试验的事后分析,纳入进展至透析的 2 型糖尿病合并慢性肾脏病患者 590 例(达依泊汀组 298 例,安慰剂组 292 例)。
主要发现
- 达依泊汀组与安慰剂组透析时血红蛋白分别为 11.3±1.6 和 9.5±1.5 g/dL(P<0.001)。
- 全因死亡分别为 31 例(10.4%)和 28 例(9.6%),HR 1.16(95% CI 0.69-1.93)。
- 心血管死亡分别为 15 例(5.0%)和 13 例(4.5%),HR 1.21(95% CI 0.58-1.93)。
- 非致死性心肌梗死或心力衰竭风险无差异。
- 卒中分别为 8 例(2.8%)和 1 例(0.3%),HR 8.6(95% CI 1.1-68.7)。
临床怎么用
- 对于接近透析的 2 型糖尿病合并 CKD 伴轻中度贫血患者,透析前使用 ESA 纠正贫血需个体化权衡,警惕卒中风险。
局限性
- 为随机对照试验的事后亚组分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Evidence from clinical trials to guide patient preparation for maintenance dialysis therapy is limited. Although anemia is associated with mortality and cardiovascular (CV) disease in individuals initiating maintenance dialysis therapy, it is not known if treatment of anemia before dialysis therapy initiation with erythropoiesis-stimulating agents alters outcomes. STUDY DESIGN: Post hoc analysis of a randomized controlled trial. SETTING & PARTICIPANTS: Participants with type 2 diabetes and chronic kidney disease who progressed to dialysis therapy (n=590) in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). EXPOSURE: Randomized treatment assignment (darbepoetin vs placebo). OUTCOMES: All-cause mortality, CV mortality, nonfatal myocardial infarction, heart failure, and stroke within the first 180 days of dialysis therapy initiation. ANALYTICAL APPROACH: Proportional hazards regression. RESULTS: Overall, 590 of 4,038 (14.6%) participants initiated dialysis therapy during the trial (n=298 and 292 in the darbepoetin and placebo groups, respectively). Corresponding hemoglobin levels were 11.3±1.6 and 9.5±1.5g/dL (P<0.001). Death from any cause occurred in 31 (10.4%) participants assigned to darbepoetin and 28 (9.6%) assigned to placebo (HR, 1.16; 95% CI, 0.69-1.93), while death from CV causes occurred in 15 (5.0%) and 13 (4.5%) participants, respectively (HR, 1.21; 95% CI, 0.58-1.93). There were no differences in risk for nonfatal myocardial infarction or heart failure. Stroke occurred in 8 (2.8%) participants assigned to darbepoetin and 1 (0.3%) assigned to placebo (HR, 8.6; 95% CI, 1.1-68.7). LIMITATIONS: Post hoc analyses of a subgroup of study participants. CONCLUSIONS: Despite initiating dialysis therapy with a higher hemoglobin level, prior treatment with darbepoetin was not associated with a reduction in mortality, myocardial infarction, or heart failure in the first 180 days, but a higher frequency of stroke was observed. In the absence of more definitive data, this may inform decisions regarding the use of erythropoiesis-stimulating agents to treat mild to moderate anemia in patients with type 2 diabetes and chronic kidney disease nearing dialysis therapy initiation.
引用
- Mc Causland FR, Claggett B, Burdmann EA, et al. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2018. PMID: 30578152. doi:10.1053/j.ajkd.2018.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。